Ignite Creation Date:
2024-05-06 @ 2:25 PM
Last Modification Date:
2024-10-26 @ 1:30 PM
Study NCT ID:
NCT04311112
Status:
WITHDRAWN
Last Update Posted:
2023-02-24
First Post:
2020-03-12
Brief Title:
Safety and Efficacy of Zuretinol Acetate in Subjects With Inherited Retinal Disease
Sponsor:
Retinagenix Holdings
Organization:
Retinagenix Holdings
Study Overview
Official Title:
Safety and Efficacy of Zuretinol Acetate Oral Solution in Subjects With Inherited Retinal Disease Caused by Mutations in Retinal Pigment Epithelium Protein 65 or LecithinRetinol Acyltransferase
Status:
WITHDRAWN
Status Verified Date:
2020-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The asset was transferred to another company
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the efficacy of ZA oral solution in subjects with IRD caused by biallelic recessive RPE65 or LRAT gene mutations and phenotypically diagnosed as Lebers Congenital Amaurosis LCA or Retinitis Pigmentosa RP
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None